A Single Ascending Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1092 in Healthy Subjects, Subjects With Type 1 Diabetes Mellitus, and Subjects With Type 2 Diabetes Mellitus
Phase of Trial: Phase I
Latest Information Update: 05 Dec 2018
At a glance
- Drugs Insulin lispro (Primary) ; MK-1092 (Primary) ; Insulin glargine
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Merck Sharp & Dohme
- 29 Nov 2018 Status changed from active, no longer recruiting to completed.
- 29 Oct 2018 Planned End Date changed from 26 Oct 2018 to 30 Oct 2018.
- 29 Oct 2018 Planned primary completion date changed from 26 Oct 2018 to 30 Oct 2018.